Edition:
India

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

5.36USD
9:13pm IST
Change (% chg)

$-0.05 (-0.92%)
Prev Close
$5.41
Open
$5.41
Day's High
$5.43
Day's Low
$5.34
Volume
8,991
Avg. Vol
30,796
52-wk High
$12.50
52-wk Low
$3.25

Summary

Name Age Since Current Position

Douglas Williams

60 2019 Chairman of the Board

Andrea Pfeifer

61 2003 Chief Executive Officer

Martin Velasco

63 2019 Independent Vice Chairman of the Board

Joerg Hornstein

40 2017 Chief Financial Officer

Jean-Fabien Monin

47 2015 Chief Administrative Officer

David Lowe

2018 Interim Chief Scientific Officer

Werner Lanthaler

50 2018 Director

Roy Twyman

2019 Director

Peter Bollmann

64 2015 Non-Executive Independent Director

Thomas Graney

53 2016 Non-Executive Independent Director

Friedrich von Bohlen und Halbach

55 2015 Non-Executive Independent Director

Biographies

Name Description

Douglas Williams

Dr. Douglas E. Williams, Ph.D. is Chairman of the Board of the Company. Dr. Williams is currently the President, CEO and member of the Board of Directors of Codiak BioSciences. He was previously Biogen's Executive Vice President, Research and Development. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. During his 30+ year career in the biotechnology industry, he has played a role in the development of several novel drugs and has served on the board of numerous biotechnology companies.

Andrea Pfeifer

Prof. Dr. Andrea Pfeifer, Ph.D., has served as Chief Executive Officer of AC Immune Ltd since 2003. Prior to AC Immune she was head of Nestle's Global Research in Lausanne, Switzerland and managed a group of more than 600 people. While at Nestle, she led the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical products in a joint venture with L’Oreal, Inneov Fermete. She also co-founded the Nestle Venture Capital Fund, a Life Sciences corporate venture fund. She serves as chairwoman of the Biotechmedinvest AG Investment Fund, Basel and AB2Bio, Lausanne and is member of the Supervisory Board of Symrise AG, Holzminden. Prof. Pfeifer is a member of the CEOi Initiative on Alzheimer’s Disease. She was recognized in 2009 as Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. She holds a Ph.D. in Toxicology, Cancer Research from the University of Wuerzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, USA. She is a registered Toxicologist and Pharmacist, received her habilitation from the University of Lausanne, Switzerland and is an honorary professor at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Martin Velasco

Mr. Martin Velasco serves as Independent Vice Chairman of the Board of AC Immune Ltd. He is Member of the Audit and Finance Committee and the Compensation, Nomination and Governance Committee at the Company. He has served on the Company's Board of Directors since December 2003. He is an entrepreneur and Business Angel with experience in the IT, medical and biotech areas. He serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology Pioneer 2008 as Chairman of the Supervisory Board of Cocomore, a digital communications agency and IT services firm and as a Board Member of Aridhia, a Health Informatics company. Martin is also the Founder of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is an Ambassador of BlueOrchard, the leading private microfinance investment advisory company and a member of the Strategic Advisory Board of the EPFL.

Joerg Hornstein

Mr. Joerg Hornstein has been Chief Financial Officer of AC Immune Ltd since April 1, 2017. Prior to joining AC Immune, Mr. Hornstein served as Senior Vice President Group Controlling for Unternehmensgruppe Theo Mueller based in Luxembourg from January 2014 to March 2017. Between 2002 and 2013 he worked for Merck KGaA, a science and technology company in healthcare, life science and performance materials, where he held various senior finance roles. Amongst others, he was Chief Financial Officer for Merck’s operations in Indonesia and Merck Serono’s operations in China. Furthermore, he served as Vice President Group Controlling for Merck Group Headquarters in Germany and as Divisional Chief Financial Officer for Merck Millipore in the U.S. Mr. Hornstein holds an MBA with Distinction from London Business School and a Bachelor of Business Administration from Baylor University.

Jean-Fabien Monin

Mr. Jean-Fabien Monin has been Chief Administrative Officer of AC Immune Ltd since July 2015. He was Chief Financial Officer at the Company from March 2009. Prior to AC Immune, he held several positions during his tenure of 14 years at bioMerieux, an international in vitro diagnostics group, culminating in his nomination as Chief Financial Officer. His last position was Chief Financial Officer of bioMerieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr. Monin holds a Masters in Finance and International Business from the University of Paris-Dauphine, France.

David Lowe

Dr. David A. Lowe, Ph.D., has been Interim Chief Scientific Officer at AC Immune Ltd since October 19, 2018. He was Innovation Fellow at the Company from January 2014. Previously, he was the Chief Scientific Officer at PsychoGenics Inc., Chief Scientific Officer at Memory Pharmaceuticals (acquired by Roche), Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group in Boston, president, CEO and director of Envivo Pharmaceuticals (now Forum Pharmaceuticals), Vice President and therapeutic area head at Roche Bioscience in Palo Alto, Vice President and global therapeutic area head at Bayer AG, and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis). Dr. Lowe received his Ph.D. in Neurobiology from the University of Leeds.

Werner Lanthaler

Dr. Werner Lanthaler Ph. D. is Director of the Company. Dr. Werner Lanthaler is the CEO of Evotec AG, a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Since joining Evotec in 2009, Dr. Lanthaler has focused the company on collaborating with biotech and pharma companies and academia - supporting biotech innovation. He previously served as Chief Financial Officer at Intercell AG where he played a key role in many of the company's major milestones. During his tenure, Intercell undertook an Initial Public Offering and developed from a venture-backed biotechnology company into a global vaccine player. Dr. Lanthaler has also served as Director of the Federation of Austrian Industry, and from 1995 to 1998 was a Senior Management Consultant at McKinsey & Company. Dr. Lanthaler is a Non-Executive Member of the Board of Directors of arGEN-X and is a member of the Supervisory Board of Topas Therapeutics GmbH. He holds a Doctorate in Economics from Vienna University, a Master's degree in Business Administration from Harvard University, and a degree in Psychology.

Roy Twyman

Dr. Roy Twyman, M.D. is Director of the Company. Dr. Twyman is a neurologist and currently CEO and founder, Amron Neuroscience, LLC, a private consulting company focused on neuroscience drug development. Prior to this, Dr. Twyman spent almost 20 years at Janssen Research & Development, LLC (a Johnson & Johnson company) and was a member of the Neuroscience Therapeutic Area Leadership team responsible for clinical R&D and strategic planning of CNS neurology and psychiatry pipeline products. From 2012 to March 2018, he was a Senior Vice President in the Neuroscience Therapeutic Area overseeing the Alzheimer's Disease Area. He currently participates as an independent board member or as a scientific advisory board member for a number of small biotech or pharmaceutical companies.

Peter Bollmann

Dr. Peter Bollmann, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since December 2015. He is Chairman of the Audit and Finance Committee at the Company. He has management and finance experience in Switzerland and abroad as Chief Executive Officer, Chief Financial Officer and member of the board. His broad industry experience embraces biotechnology and medical technology firms including previous Board positions with Cytos Biotechnology and Prionics.

Thomas Graney

Mr. Thomas Graney has been Non-Executive Independent Director at AC Immune Ltd since November 15, 2016. He is Member of the Audit and Finance Committee and the Compensation, Nomination and Governance Committeeat the Company. He is the Senior Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc. since September 2017. Prior to joining Vertex in September 2017, Mr. Graney served as the Chief Financial Officer (CFO) and Senior Vice President of Finance and Corporate Strategy at Ironwood Pharmaceuticals. At Ironwood, he was responsible for Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations. Before Ironwood, he was with Johnson & Johnson for 20 years in various roles in the U.S. and abroad. Most recently he was the Worldwide Vice President of Finance and CFO for Ethicon Surgical Care, a medical device company. In addition, Mr. Graney has global experience that spans corporate development, commercial strategy, portfolio management and supply chain management. A Chartered Financial Analyst charterholder, Mr. Graney holds a B.S. in Accounting from the University of Delaware and an MBA in Marketing Finance and International Business from the Leonard N. Stern School of Business at New York University.

Friedrich von Bohlen und Halbach

Dr. Friedrich von Bohlen und Halbach, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since October 2015. He is co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. He brings industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997 (now SYGNIS Pharma AG) and served as the company’s Chief Executive Officer. He is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Novaliq GmbH. He holds a Ph.D. in Neurobiology from the Swiss Federal Institute of Technology in Zurich, Switzerland.